Erdosteine

Erdosteine belongs to the pharmacological class of Mucolytics, which helps in relieving the conditions of respiratory infection and Chronic Obstructive Pulmonary Disease.

Erdosteine is completely absorbed in the GIT with its peak plasma concentration of 1 hour. Erdosteine undergoes first-pass metabolism to N-thiodiglycol-homocysteine (active metabolite). The Elimination of Erdosteine occurs via urine (as active metabolite and sulfates). The elimination half-life was found to be 1.46 hours (erdosteine); 1.62 hours (N-thiodiglycol-homocysteine).

The common side effects of Erdosteine are urticaria, diarrhea, epigastric pain, nausea, vomiting, and taste alterations.

Erdosteine is found to be available in the form of Oral capsules.

Erdosteine is available in the U.S., Canada, E.U., India, Australia, and Japan.

Erdosteine belongs to the pharmacological class of expectorants, which helps in relieving the conditions of respiratory infection and Chronic Obstructive Pulmonary Disease.

Erdosteine is said to regulate the production of mucus in the airway as well as regulates its viscosity while enhancing mucociliary transport. This leads to an increase in expectancy. Erdosteine also shows inhibition against the effects of free radicals from cigarette smoke.

Erdosteine had been approved for relieving symptoms as well as also for the treatment and maintenance of episodes of respiratory infection and Chronic Obstructive Pulmonary Disease.

Erdosteine is available in the form of Oral capsules.

Erdosteine can be used in the treatment of the following conditions:

• Respiratory infection
• Chronic Obstructive Pulmonary Disease

Erdosteine can help to relieve symptoms and also for the treatment and maintenance of respiratory infection and Chronic Obstructive Pulmonary Disease.

Erdosteine is approved for the treatment in the following clinical indications/conditions:

• Respiratory infection
• Chronic Obstructive Pulmonary Disease

Capsules

To be swallowed as a whole with water.

Capsules

300mg

Capsules

Smoking cessation and maintaining health are a must.

Caffeine should be avoided or limited to use as it might lead to the risk of nausea, palpitations, nervousness, rapid heartbeat, etc.

Alcohol intake should be avoided in patients, especially those with an underlying liver disorder or liver dysfunction.

The dietary restrictions should be individualized as per the patient's requirements.

Erdosteine may be contraindicated under the following conditions:

• Hypersensitive to the ingredients of the medication

The adverse reactions related to Erdosteine can be categorized as follows:

• Urticaria
• Diarrhea
• Erythema
• Epigastric pain
• Vomiting
• Angioedema
• Nausea
• Oedema
• Taste alteration
• Eczema
• Headache

The clinically relevant drug interactions of Erdosteine are briefly summarized here:

• Dextroamphetamine

Erdosteine decreases levels of dextroamphetamine by increasing renal clearance. Use with Caution/Monitor.

• Dichlorphenamide

Dichlorphenamide and Erdosteine both decrease serum potassium. Use with Caution/Monitor.

• Dichlorphenamide, Erdosteine. Either increases the toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

• Lisdexamfetamine

Erdosteine decreases levels of lisdexamfetamine by increasing renal clearance. Use with Caution/Monitor.

• Methamphetamine

Erdosteine decreases levels of methamphetamine by increasing renal clearance. Use with Caution/Monitor.

• Methylenedioxymethamphetamine

Erdosteine decreases levels of methylenedioxymethamphetamine by increasing renal clearance. Use with Caution/Monitor.

• Pseudoephedrine

Erdosteine decreases the effects of pseudoephedrine by an unknown mechanism. Use with Caution/Monitor. Urinary excretion of indirect-acting alpha/beta agonists (e.g., pseudoephedrine) may increase when administered concomitantly with urinary acidifying agents, resulting in lower serum concentrations.

The common side effects of Erdosteine include the following:

• Urticaria
• Diarrhea
• Erythema
• Epigastric pain
• Vomiting
• Angioedema
• Nausea
• Oedema
• Taste alteration
• Eczema
• Headache

Pharmacodynamics

N.A.

Pharmacokinetics

• Absorption: Rapidly absorbed from the gastrointestinal tract. Time to peak plasma concentration: Approx. 1 hour.
• Distribution: Plasma protein binding: 50-86%.
• Metabolism: Undergoes rapid first-pass metabolism to N-thiodiglycol-homocysteine (active metabolite).
• Excretion: Via urine (as active metabolite and sulfates). Elimination half-life: 1.46 hours (erdosteine); 1.62 hours (N-thiodiglycolyl-homocysteine).

1. https://www.mims.com/philippines/drug/info/erdosteine?mtype=generic#:~:text=Significant: Epigastric pain, taste alteration,Nervous system disorders: Headache.
2. https://go.drugbank.com/drugs/DB05057
3. https://www.medindia.net/doctors/drug_information/erdosteine.htm
4. https://patients.smarterhealth.sg/drugs-medicines/erdosteine/
5. https://www.medicines.org.uk/emc/product/287/smpc#gref